Seasoned leader with over 18 years of experience in clinical development with leading multinational companies as well as biotech companies, including as Chief Medical Officer, Head of Global Clinical Science, Medical Director and Clinical Research Physician. Responsible for development pathway design, trial design, regulatory strategy, clinical operations, efficacy and safety assessments in support of global and regional trials which have resulted in successful registrations for multiple compounds in multiple indications, in the US and China, including Strattera and Cymbalta launch in China with indications of ADHD and depression respectively, Zyprexa bipolar depression in both US and China. Leadership responsibilities included managing direct/indirect reports of multi-functional teams, vendors and contractors in the US, China and Japan. Multiple interactions with US FDA and China SFDA, led more than 30 cross border (US and China) clinical development programs in different clinical stages and different therapeutic areas. Prior to joining industry, 11 years of experience as a clinician in the roles of Associate Professor, Associate Consultant Physician, with a leading academic hospital in Shanghai China, also served as a key member of task force of Chinese treatment and diagnosis guideline for dementia. MD-PhD specialized in neuroimaging with EMBA training and certification.
address: A-216, No.56 Dongzhimen Wai Xie St. Chaoyang, Beijing 100027, China
tel: +86 10 6462 0528
address: Room 1502, Building C Poly West Bund Center, No.275, Ruiping Rd, Xuhui Disrict, Shanghai 200232, China